Axadin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Axadin

Quick Facts

Property Description
Active ingredient Nizatidine
Form Oral dosage forms (Capsule, Tablet, Solution)
Pharmacological class H2-receptor antagonist
Common use Reducing stomach acid
Origin Synthetic compound

Core Identity and General Purpose

Axadin is a synthetic, single-active-ingredient medication containing the chemical entity Nizatidine (C12H21N5O2S2), which is officially classified as a histamine H2-receptor antagonist or H2-blocker. This drug belongs to the class of antisecretory agents and is designed to act systemically following absorption. The primary purpose of Nizatidine is to create conditions for healing by reducing the amount of acid produced by the stomach.

Nizatidine is a later-generation H2-blocker, clinically recognized for its high bioavailability and for demonstrating minimal inhibitory effect on major hepatic enzyme systems, a differentiating feature within its pharmacological class. Its fundamental function is achieved through the competitive reversible inhibition of the specific H2-receptors on gastric parietal cells. The general benefit for patients is the alleviation of pain and discomfort associated with common issues like heartburn and general acid indigestion by lowering the acid load.

Axadin is administered via the oral route of administration and is supplied as a single active ingredient product. The medication is available in common forms like the hard gelatin capsule, the tablet, and an oral solution. The specific formulation of Axadin ensures that the active component, Nizatidine, is effectively delivered to support its role as an antisecretory agent in the gastric lining, providing reliable acid reduction.

What side effects are possible with Axadin?

Possible Side Effects and Safety Information

The official safety profile of Axadin (Nizatidine) is structured by government regulatory agencies to communicate the scope of documented adverse reactions and safety characteristics, classifying potential effects by frequency and the body systems involved.


Adverse Reaction Scope

The drug's safety information details effects across multiple System-Organ Classes, including Gastrointestinal, Nervous System, Hepatobiliary, Dermatological, and Hematologic systems. The most frequently reported effect in clinical trials is headache, which is classified as Very Common.

Common adverse reactions documented in regulatory sources include diarrhea, vomiting, dizziness, somnolence (drowsiness), insomnia, rash, and sweating.

Serious Adverse Reactions

The labeling documents rare but clinically significant adverse events, such as hepatocellular injury (liver damage) and associated jaundice (yellowing of the skin or eyes), which are generally reversible after discontinuation. Extremely rare events, including fatal thrombocytopenia (a severe drop in platelets) and severe hypersensitivity reactions like anaphylaxis, are also documented.


Regulatory Safety Constraints

The use of Axadin is subject to specific safety notes. The symptomatic response to Nizatidine therapy does not preclude the presence of gastric malignancy; therefore, symptom relief should not rule out the possibility of stomach cancer.

Population-Specific Safety:

Since the drug is primarily eliminated through the kidneys, the official labeling notes that dosage adjustment is required for patients with moderate to severe renal impairment to prevent drug accumulation. The safety profile also notes that liver enzyme elevations and associated abnormalities are typically reversible after discontinuation of the medication.

Overdose and Emergency Response

Overdose and when to seek help

Officially documented information regarding overdosage with Axadin (Nizatidine) is based primarily on limited human clinical experience and observations from high-dose animal studies. For this reason, specific severe or life-threatening outcomes in humans are not explicitly detailed in government regulatory labels.


Documented Manifestations

Overdose manifestations are mainly inferred from toxicology studies involving very large oral doses in animals. These studies suggest the potential for cholinergic-type effects, which may include clinical signs such as increased lacrimation (tearing), salivation, emesis (vomiting), miosis, and diarrhea.


Required Emergency Actions and Management

Immediate medical attention is officially required in the event of any suspected overdosage. Regulators explicitly mandate that individuals must seek medical help or contact a Poison Control Center right away. In the United States, calling 911 is advised for immediate emergency assistance.

Treatment for Nizatidine overdosage is described as strictly symptomatic and supportive therapy. There is no specific antidote known. Management considerations include the possible use of measures such as activated charcoal, emesis, or gastric lavage to reduce drug absorption. Clinical monitoring is necessary, but the ability of haemodialysis to remove Nizatidine from the body has not been conclusively demonstrated in official regulatory documents.

Therapeutic Uses of Axadin

Axadin (Nizatidine) is commonly used across therapeutic domains focused on managing symptoms linked to organ-specific functional stress, particularly issues arising from stomach acid. The primary goal of this medication provides support that helps ease the overall symptom burden associated with acid-peptic disorders. Axadin is considered relevant within clinical settings where supportive symptom management is appropriate, applied across relevant therapeutic areas.

This medication is commonly used to help with conditions characterized by recurrent or episodic manifestations, such as Gastroesophageal Reflux Disease (GERD) and erosive esophagitis, as well as in the symptomatic management of active duodenal ulcer and benign gastric ulcer. It is also applied in addressing episodes of sour stomach and general acid indigestion.


Treating and Protecting Against Peptic Ulcers

Axadin is commonly used in the symptomatic management of conditions involving inflammatory or irritative processes. It is relevant for easing the discomfort associated with these sores and is often applied as maintenance therapy to support the patient during periods of potential recurrence after initial healing.

“The consistent relief of acid-related pain supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Chronic Acid Exposure Axadin helps address symptom clusters that may become intense or disruptive, such as frequent heartburn and acid irritation of the esophagus, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Axadin (Nizatidine)

Axadin use is defined by strict population eligibility rules and contraindications documented in official government labeling.

Contraindications and Restrictions

Category Population/Condition Regulatory Status
Absolute Contraindication Known hypersensitivity to Nizatidine or other H₂-receptor antagonists Prohibited Use
Age Restriction Children younger than 12 years of age Use Not Established

Conditional Use Requirements

Axadin may be used only under specific conditions for certain populations:

  • Renal Impairment: Patients with moderate to severe renal impairment (Creatinine Clearance CrCl le 50 mL/min) require restricted use; the dose must be adjusted to prevent drug accumulation.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed (FDA Category B). It is not recommended during lactation as Nizatidine is secreted into breast milk.
  • Gastric Ulcer: For patients presenting with gastric ulcer symptoms, official labeling requires that malignancy must be formally excluded before treatment is initiated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Axadin (Nizatidine) is primarily defined by its effects on gastric acid and its documented neutrality toward key metabolic pathways. All documented interaction information is derived from official regulatory labeling.

Pharmacokinetic and Functional Interactions

Interaction Partner Official Regulatory Outcome Interaction Type
Antacids (aluminum/magnesium hydroxides) Decreases the absorption and exposure of Axadin by approximately 10%. Reduced Axadin Exposure
Charcoal Reduces the absorption and exposure of Axadin by up to 20%. Reduced Axadin Exposure
Drugs dependent on acidic gastric pH Axadin reduces gastric acidity, which can reduce the gastric absorption of these medicines. Reduced Co-drug Exposure
Salicylates (very high dosage, e.g., 3,900 mg daily) May increase the absorption of salicylates, leading to higher serum levels. Increased Co-drug Exposure

Metabolic Profile and Restrictions

Axadin does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system. Consequently, regulatory documents state that drug interactions mediated by the inhibition of hepatic metabolism are not expected to occur. There are no medicinal product combinations formally classified as contraindicated in official regulatory documents due to drug-drug interaction risks. Furthermore, official labels do not specify mandatory administration separation windows for any interacting products. Regulatory studies have also explicitly documented no clinically significant interaction with numerous substances, including Warfarin, Theophylline, Phenytoin, and Lorazepam.

Mechanism of Action

How Axadin Works

Axadin acts exclusively as a peripheral anti-secretory agent by engaging two core mechanistic domains that govern acid production in the stomach. Its action is centered on interrupting the principal chemical signal for secretion, histamine.


Competitive Blockade of the Histamine H2 Receptor

This domain covers the molecular interaction where the active ingredient, Nizatidine, acts as a competitive antagonist against the histamine H2 receptors ( H2 R) on gastric parietal cells. By occupying these receptors, Axadin prevents the endogenous mediator, histamine, from binding and initiating the cell's acid-producing cycle.


Inhibition of the Gastric Acid Signaling Cascade

This domain explains the resulting cellular consequence where the H2 R blockade interrupts the G s-protein and cAMP signaling pathway inside the parietal cell. This suppression functionally deactivates the key steps needed to mobilize and activate the H^+/ K^+-ATPase (proton pump), leading directly to a reduction in hydrochloric acid ( HCl) secretion and a physiological elevation of gastric pH.

Dosage and Administration Information

Administration Protocol

Axadin is administered via the oral route using approved dosage forms including the capsule, tablet, and oral solution. The administration protocol is determined by the required duration of therapy: short-term treatment for active conditions or long-term maintenance protocols.


Dosing and Frequency

For active treatment of ulcers or erosive esophagitis, the common regimen is 150 mg taken twice daily, or an alternative 300 mg dose taken once daily at bedtime. Long-term maintenance therapy to prevent duodenal ulcer recurrence uses a sustained dose of 150 mg taken once daily, also scheduled at bedtime. The medication can be taken without regard to meals. If the oral solution is used, it must be measured precisely with a calibrated measuring device.


Procedural Instructions

Active treatment protocols are generally defined by a duration of 4 to 12 weeks, while maintenance use is approved for continuation for up to 1 year. A key procedural requirement involves mandatory dose modification in patients with moderate or severe renal impairment due to the drug’s primary renal excretion. The dose must be reduced to prevent accumulation. For adolescents age 12 years and older, the dose for esophagitis matches the standard adult 150 mg twice-daily regimen. Should a dose be missed, the standard protocol is to take it as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Axadin: Recent Clinical Evidence

The following is an overview of key clinical trials and research findings that examined the investigational drug Axadin.


Phase 3 Clinical Trial Results

Research has explored whether the study drug may influence mild-to-moderate symptoms of Condition X. These large-scale studies evaluated whether the investigational drug influenced the time to symptom improvement and sustained changes in reported pain scores across all age groups examined. The trials explored whether participants reported changes in symptoms during the early phase of investigation.


Subgroup Analysis: Combination Regimen

Research examined whether the combination regimen was associated with changes in reported outcomes and inflammation markers. Some studies, based on initial laboratory observations, examined the combination of the investigational drug with lifestyle factors.

Study Population

Subgroup Examined Exclusion Criteria
A subgroup analysis assessed data from participants who also had Type 2 Diabetes. Participants presenting with pre-existing kidney conditions were generally excluded from the study protocols.

Long-term Safety and Data Profile

Research assessed data regarding the investigational drug’s extended-duration exposure and related changes in reported quality of life. Studies examined reported data on flare-up frequency related to the investigational drug. These long-term studies provide important data on the potential effects of Axadin over a sustained period, helping to provide a more complete picture of the research findings.

Frequently Asked Questions (FAQ)

Common questions about Axadin (FAQ)


Q: How is Axadin different from other similar treatments I've seen advertised?

Axadin belongs to the class of H2-receptor antagonists, which work to reduce stomach acid. Official product information notes that, unlike some older acid-reducing medications, the active ingredient in Axadin (Nizatidine) demonstrates a minimal inhibitory effect on major hepatic enzyme systems. This is described as a differentiating feature within its pharmacological class.


Q: How long does it usually take to notice any change after starting Axadin?

Axadin's function is centered on reducing the amount of acid produced by the stomach. Clinical studies have explored the time it takes for symptom improvement, and official protocols for active treatment generally define a duration of four to twelve weeks. The effect of reduced stomach acid may be apparent within the early phase of the investigation.


Q: What is the main concern people have about Axadin?

A key regulatory safety note indicates that the symptomatic response to Axadin therapy does not preclude the presence of gastric malignancy (stomach cancer); symptom relief should not be used to rule out this possibility. Additionally, since the drug is eliminated by the kidneys, official labeling notes that dose adjustment is a requirement for patients with moderate to severe renal impairment to help prevent drug accumulation.


Q: Can Axadin be taken with common pain relievers like ibuprofen?

Regulatory documents advise that Axadin's acid-reducing effect may change the absorption of certain other medications. Furthermore, some common pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs like ibuprofen), may contribute to the same stomach irritation or ulcers Axadin is prescribed to help treat. Reviewing the labels of all over-the-counter products is part of informed use.


Q: Are there any specific supplements or vitamins that interact with Axadin?

Official patient guidance suggests that individuals should discuss all supplements and herbal products they are taking with a healthcare professional. This is because these products may contain substances that could potentially interfere with how Axadin is absorbed or how it functions in the body.


Q: Why is Axadin sometimes used for a condition that isn't its primary purpose?

Patient guidance notes that while Axadin is approved for specific uses, a healthcare professional may decide to prescribe it for purposes not listed in the approved official labeling. This falls outside of the officially approved uses and is considered a decision for a healthcare professional.


Q: Is Axadin suitable for people over 65?

Appropriate studies have not shown unique problems specific to the geriatric population. However, regulatory information notes that older patients may be more sensitive to the drug's effects and are more likely to have age-related kidney problems. Because the drug is primarily eliminated through the kidneys, official documents note that dose adjustment may be required.


Q: Can I drive a car while I am taking Axadin?

Official labeling documents central nervous system ( CNS) side effects, including dizziness and drowsiness (somnolence), as common adverse reactions. Due to the documented risk of these effects, the ability to safely operate machinery or drive may be affected, requiring awareness.


Q: Does Axadin carry a Black Box Warning?

According to the official FDA prescribing information, Axadin does not carry a Black Box Warning. A Black Box Warning is the highest safety alert issued by the FDA to call attention to serious or life-threatening risks.


Q: Can Axadin affect lab test results?

Yes. Official prescribing information states that the medication may cause false-positive results for urobilinogen in some commercial urine tests. Informing laboratory and medical staff about the use of this medicine is part of the standard procedure before having lab work done.


Q: Does alcohol interact negatively with Axadin?

Regulatory patient guidance suggests limiting or avoiding alcohol as part of lifestyle changes that may support the medication's effectiveness in treating conditions like ulcers. Alcohol itself is known to increase stomach acid production, which can counteract the intended effect of Axadin.


Q: How long does Axadin stay in your system after you stop taking it?

The medication is rapidly eliminated by the body. Official pharmacokinetic data indicates an elimination half-life of 1 to 2 hours in individuals with normal kidney function. This means that more than 90% of an oral dose is typically excreted in the urine within about 12 hours.


Q: Is Axadin known to interact with herbal remedies like St. John's Wort?

Regulatory guidance advises that the discussion of all herbal products and remedies with a healthcare provider is the recommended practice. This ensures that any potential, known, or unknown interactions are reviewed before combining Axadin with any herbal substance.


Q: Why are people asked about their mental health history before starting Axadin?

Official regulatory labeling documents rare cases of reversible mental confusion and other Central Nervous System ( CNS) effects as possible adverse reactions. Although uncommon, the official safety profile includes these events, which helps the prescriber evaluate the potential risk.


Q: Are there any activities I should avoid while on Axadin?

Due to the documented risk of CNS side effects like dizziness and drowsiness (somnolence), the risk of these effects means that activities requiring full mental alertness may be impacted, such as operating heavy machinery or performing tasks that could be hazardous if you feel dizzy or drowsy.


Q: Can Axadin interact with cold and flu medicines?

Since Axadin is a strong acid reducer, it may change the absorption rate of other medications you take by mouth. Cold and flu medicines often contain multiple active ingredients that may be sensitive to changes in stomach acidity. The recommended practice is to discuss all over-the-counter cold and flu products with a healthcare professional.


Q: Do I need to inform my dentist that I am taking Axadin?

Patient guidance recommends informing any medical professional treating you, including your dentist, that you are taking Axadin. This is specifically advised because the medication can cause unusual results with certain medical tests that a dentist or other specialist might order.


Q: How is Axadin usually stopped or discontinued?

The official protocol for stopping Axadin depends on the duration of therapy. Short-term treatment is generally stopped after the prescribed period. The regulatory documents detailing maintenance therapy do not specify a mandatory tapering schedule for discontinuation, but any change in long-term use is a matter for discussion with a healthcare professional.


Q: What does the term 'contraindication' mean for Axadin?

A contraindication means that the medication should absolutely not be used under certain conditions, as the risk outweighs any potential benefit. For Axadin, an absolute contraindication is a known hypersensitivity (severe allergic reaction) to Nizatidine or other similar H2-receptor antagonist drugs.


Q: Can Axadin cause stomach upset or nausea?

The official safety profile for Axadin includes reports of several gastrointestinal adverse reactions. The list explicitly documents diarrhea and vomiting as common effects. The detailed safety profile contains the comprehensive list of documented adverse reactions.


Q: What are the signs of a serious, but rare, side effect of Axadin?

Serious, though rare, adverse reactions are documented in the official labeling. These include hepatocellular injury (liver damage) which may present as jaundice (a yellowing of the skin or eyes), and severe blood disorders like fatal thrombocytopenia (signs may include unusual bruising or bleeding). Regulatory documents emphasize that these effects are generally reversible after discontinuation.

How should Axadin be stored and disposed of?

Axadin (Nizatidine) must be stored and handled according to the official regulatory instructions to maintain product quality.

Storage Conditions

Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The oral solution formulation must not be frozen.

Protection: The product must be kept in its original container, which must remain tightly closed to protect it from moisture and light. The medication must be kept out of the sight and reach of children.

Stability: The prepared oral solution has a limited in-use stability period and must be discarded after the time specified on the labeling.

Disposal Instructions

Unused or expired Axadin should be disposed of primarily through an authorized drug take-back program. If a program is unavailable, the product may be mixed with an unappealing substance and sealed in a bag for household trash disposal. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Axadin found in:

A-Z Index: